Isomorphic Labs, the Google-backed AI drug discovery company, secured a $2.1 billion Series B round as it looks to scale its AI drug design engine and move therapeutic programs closer to clinical development. The financing was led by Thrive Capital and included participation from existing and new investors. The company described its underlying system, IsoDDE, as an integrated drug design and development engine rather than a software product to be licensed. It said proceeds will support continued scaling of model development, pipeline advancement, and hiring across AI, engineering, drug design, and clinical development. Isomorphic emphasized an internal therapeutic focus on oncology and immunology while keeping the longer-term model capability broad. The company also reiterated existing partnerships with major pharma collaborators, indicating the funding is aimed at both platform scale and translation. For the biotech industry, the round signals that large-scale capital continues to reward AI-first approaches—particularly those that can demonstrate productivity from model outputs into real development plans.